Compare UBXG & NEPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | UBXG | NEPH |
|---|---|---|
| Founded | 2018 | 1997 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | | Medical/Dental Instruments |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 66.0M | 60.0M |
| IPO Year | 2024 | 2004 |
| Metric | UBXG | NEPH |
|---|---|---|
| Price | $1.98 | $5.19 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $6.00 |
| AVG Volume (30 Days) | 17.5K | ★ 62.1K |
| Earning Date | 12-22-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 0.14 |
| Revenue | ★ $29,674,534.00 | $17,930,000.00 |
| Revenue This Year | N/A | $33.32 |
| Revenue Next Year | N/A | $12.27 |
| P/E Ratio | ★ N/A | $36.44 |
| Revenue Growth | N/A | ★ 32.36 |
| 52 Week Low | $1.62 | $1.39 |
| 52 Week High | $4.64 | $6.42 |
| Indicator | UBXG | NEPH |
|---|---|---|
| Relative Strength Index (RSI) | 42.94 | 49.17 |
| Support Level | $1.93 | $4.80 |
| Resistance Level | $2.09 | $5.97 |
| Average True Range (ATR) | 0.15 | 0.42 |
| MACD | -0.01 | -0.03 |
| Stochastic Oscillator | 10.81 | 38.76 |
U-BX Technology Ltd focuses on providing value-added services using artificial intelligence-driven technology to businesses in the insurance industry, including insurance carriers and brokers. Its main offerings include three services/products: digital promotion services, risk assessment services, and value-added bundled benefits. The PRC operating entities help their institutional clients gain visibility on various social media platforms and generate revenue based on consumers' clicks, views, or clients' promotion time on these channels. U-BX Beijing developed a unique algorithm named the Magic Mirror. The majority of revenue comes from digital promotion services. Geographically, all of the company's revenue is derived from Mainland China.
Nephros Inc is a commercial-stage company that develops and sells high-performance water solutions to the medical and commercial markets. In medical markets, it sells water filtration products and waterborne pathogen detection products. In commercial markets, the company manufactures and sells water filters that improve the taste and odor of water and reduce biofilm, bacteria, and scale build-up in downstream equipment. The company's subsidiary is engaged in the development of its second-generation hemodiafiltration system and other products focused on improving therapies for patients with renal disease. The company generates almost all of its revenue from product sales and a small amount from royalty revenue and other revenues.